The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome
- 1 February 1995
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 28 (2), 143-160
- https://doi.org/10.2165/00003088-199528020-00005
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisAntimicrobial Agents and Chemotherapy, 1993
- Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and TobramycinDICP, 1991
- Routine monitoring of serum vancomycin concentrations: waiting for proof of its value.1987
- Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistanceAntimicrobial Agents and Chemotherapy, 1987
- Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.1987
- Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbitsJournal of Antimicrobial Chemotherapy, 1986
- Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1985
- Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigsAntimicrobial Agents and Chemotherapy, 1985
- Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumoniaThe American Journal of Medicine, 1984
- The Association of Aminoglycoside Plasma Levels with Mortality in Patients with Gram-Negative BacteremiaThe Journal of Infectious Diseases, 1984